Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 211 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Tucatinib in Combination with Trastuzumab and Capecitabine Provides Survival Benefits and... December 7, 2022 New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... November 22, 2019 Load more HOT NEWS Axicabtagene Ciloleucel Results in High Response Rates and Durable Remissions as... Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... Happy 29th Birthday OncoLink!
